Containment Technology Forum: Applying ICH Q9 Principles to Selecting Containment Technology

3–4 December 2008
Barcelona, Spain

Register Online Now!


Seminar Leaders

Johannes Rauschnabel, Robert Bosch GmbH, Germany
Daniel De Grande, De Grande Consulting, Belgium


  • Develop successful solutions to current containment issues
  • Consider assessment tools such as ICH Q9 and the new ISPE Risk-MaPP Baseline® Guide
  • Establish a network to support you with on-the-job challenges – including an introduction to ISPE’s Containment Community of Practice (COP)


Increasing containment is necessary to minimise contamination of the operator environment and avoid cross-contamination from one product to the other. Each situation needs to be evaluated on a case-by-case basis, using risk assessment tools such as ICH Q9 and ISPE’s Risk-MaPP Baseline® Guide to identify the appropriate risk controls, as well as set health-based limits to address both cross-contamination and operator protection.

To select appropriate containment technology, a partnership of healthcare professionals with focus on identification of hazards, exposure assessments, risk evaluation and implementation of risk controls - as well as considering the economic and regulatory impact of non-compliance – and engineers has to be implemented.

Both, speakers from industry experts and subject matter experts will use a series of case studies, workshops and update sessions, to enable participants to develop successful solutions to current containment issues. 3 interactive workshops on given scenarios help to develop containment concepts “hands-on” and learn from each other. The seminar offers participants a great opportunity to establish a network of supporting resources for risk assessments and engineering for manufacturing pharmaceutical compounds in their work setting.


Take Back To Your Job

  • An introduction to ISPE's Risk-MaPP Baseline Guide and ts application
  • A clear understanding of hazard, risk and exposure and how they affect each other
  • Practical learning from case studies including engineering, risk approach, process design, operational procedures and operator training through presentations and workgroups
  • Successful solutions to current containment issues
  • A tool kit to help select risk controls and engineered solutions that balance product quality and operator protection – including an introduction of the Containment COP

Agenda

Wednesday, 3 December

10.00 – 10.15 Welcome and Introduction
Johannes Rauschnabel, Robert Bosch GmbH (Germany)
Daniel De Grande, De Grande Consulting (Belgium)

10.15 – 11.15 Containment Approach at Boehringer Ingelheim
Jürgen Fleckenstein, Boehringer Ingelheim (Germany)

  • OEB determination at Boehringer Ingelheim
  • GMP and containment
  • Risk management

11.15 – 12.15 Case Study 1: Contained Facility for Enzyme Production
Bent Christensen, Novozymes (Denmark)

  • Extreme OEL at high production volumes

12.15 – 13.45 Lunch and Networking Break

13.45 – 14.00 Introduction to Workgroup Tasks/Case Studies
Johannes Rauschnabel, Robert Bosch GmbH (Germany)
Daniel De Grande, De Grande Consulting (Belgium)
Richard Denk, Hecht Anlagenbau (Germany)

  • Three Case studies to be elaborated in four groups

14.00 – 15.45 Workgroups
Moderators: Johannes Rauschnabel, Robert Bosch GmbH (Germany)
Daniel De Grande, De Grande Consulting (Belgium)
Richard Denk, Hecht Anlagenbau (Germany)

  • Case study 1: Containment for OSD manufacture
  • Case study 2: Containment for sterile cytotoxics
  • Case study 3: API manufacture

15.45 – 16.15 Coffee and Networking Break

16.15 – 16.30 Workgroups (continued)
Moderators: Johannes Rauschnabel, Robert Bosch GmbH (Germany)
Daniel De Grande, De Grande Consulting (Belgium)
Richard Denk, Hecht Anlagenbau (Germany)

  • Case study 1: Containment for OSD manufacture
  • Case study 2: Containment for sterile cytotoxics
  • Case study 3: API manufacture

16.30 – 17.45 Presentation of Results

17.45 – 18.00 Questions and Answers, Close of Day 1
Johannes Rauschnabel, Robert Bosch GmbH (Germany)
Daniel De Grande, De Grande Consulting (Belgium)

17.30 – 18.30 Networking Reception


Thursday, 4 December

09.00 – 09.15 Review of Day 1, Introduction to Day 2
Johannes Rauschnabel, Robert Bosch GmbH, (Germany)
Daniel De Grande, De Grande Consulting, (Belgium)

09.15 – 10.15 Aseptic Containments for Filling of Liquid Products
Mathias Kreher, Robert Bosch GmbH (Germany)

  • GMP vs. IH
  • Containment isolator
  • Containment RABS
  • Case studies

10.15 – 10.45 Coffee and Networking Break

10.45 – 11.45 Risk-MaPP – Applying a Risk-based Approach to the Manufacture of Pharmaceutical Products
Paul Wreglesworth, Astra Zeneca (UK)

  • ISPE’s Risk-MaPP Baseline Guide
  • Hazard vs. risk
  • Science-based decision making
  • When to dedicate or segregate

11.45 – 12.45 Case Study 2: Safety and Efficiency through Containment Manufacturing: NewCon project Illertissen/Germany
Holger Weyhers, Pfizer (Germany)

  • Stay tuned for future session updates

12.45 – 14.15 Lunch and Networking Break

14.15 – 14.30 Introduction to ISPE and COP Containment
Kate McCormick, ISPE (UK)
Richard Denk, Hecht Anlagenbau (Germany)

14.30 – 15.15 Case Study 3: High Level Containment OEB5
Joost Nieuwlaat, JOA (Netherlands)

  • Pros and cons of high level containment valves
  • Impact to utilities, dedusting and process infrastructure
  • Design considerations dedusting system
  • Example integrated project approach vendor/end use

15.15 – 16.15 Questions and Answers, Close of Seminar
Johannes Rauschnabel, Robert Bosch GmbH (Germany)
Daniel De Grande, De Grande Consulting (Belgium)